Safety and Dosage Study of VX-433 in Healthy People
Part of Brain & nervous system clinical trials.
This is a first-in-human study testing a new drug called VX-433 to see how safe it is and how the body handles it. Vertex Pharmaceuticals is running this early-stage trial to understand the right dosage and side effects in healthy volunteers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Healthy adult with BMI (body weight relative to height) between 18.0 and 30.0
- Body weight greater than 50 kg (about 110 pounds)
- Non-smoker, or quit smoking at least 3 months ago with proof at screening
- No fever, cold, flu, or other acute illness in the past 14 days
- No conditions that significantly affect how your body absorbs medicines
- If female: not pregnant, not breastfeeding, and able to avoid pregnancy for 90 days after the study ends
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new medication called Lu AH69593 is safe and well-tolerated in healthy adults and people with narcolepsy type 1. Researchers want to understand how the drug affects the body and whether it could help treat excessive daytime sleepiness.
This study tests whether a new medication called ALKS 2680 can help people with narcolepsy type 1 stay more awake and alert during the day. Narcolepsy type 1 is a neurological condition where people fall asleep unexpectedly and may experience sudden muscle weakness.
This study tests an investigational drug called ALKS 2680 for people with narcolepsy type 2, a condition that causes excessive daytime sleepiness without sudden muscle weakness. The goal is to see if the drug is safe and helps reduce daytime sleepiness.
This study tests a new medication, ALKS 2680, to see if it helps reduce daytime sleepiness and other symptoms in adults with narcolepsy type 1. It may offer a new treatment option for people with this condition.
This study continues treatment with the investigational drug ALKS 2680 for people who have already completed a previous ALKS 2680 study for narcolepsy or idiopathic hypersomnia. It aims to see how safe and effective the drug is over a longer period.
This study tests a new experimental medication (QX-4533) in healthy volunteers to find the best dose and see how it works in the body. It involves taking the medication and having your health monitored closely over time.
Hear when a new Narcolepsy Type 1 (NT1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.